The OncoPlus panel is a targeted next generation sequencing (NGS)
assay that has the capability to
1,213 cancer-related genes for personalized assessments of
both solid tumors and hematological
malignancies. Variant calling in 147 genes are reportable for clinical patient care.
In the past 5 years, University of Chicago has been developing the
cancer genomics program with the goal of providing cancer patients with the best possible care in
the world at an affordable price. The design of OncoPlus panel was developed in consultation with
leading oncologists where panel not only includes the actionable targets today but also potential
In addition to mutations and ALK/RET/ROS1 gene fusions, the expanded content allows for
detection of microsatellite instability, copy number variations, and tumor mutational burden.
Microsatellite instability detection involves analysis of a collection of 338 microsatellite loci,
allowing pan-tumor detection of MSI in all cases, even those with low suspicion for MSI which have
not been tested via immunohistochemistry. The addition of copy number variations provides a range of
actionable data, including evaluation of losses in common tumor suppressor genes and amplifications
of genes such as ERBB2 (HER2), MET, and CCND1/2/3 for which inhibitors are available.
sequencing allows for robust quantification of tumor mutational burden (TMB), an emerging biomarker
with potential utility in immunotherapy selection. For cases with high TMB scores, we can also
evaluate the mutational signature of the tumor for clues to its etiology. For example, the UV
exposure signature can be used to establish a cutaneous origin of certain cases of metastatic
squamous cell carcinoma.
In addition, we provide information on check point inhibitors (PD1 and
PD1-L) by immunohistochemistry.
OncoPlus 1200 Gene NGS Panel is the most commonly used test at UChicago
for molecular profiling of patients, as it permits detection of the widest range of actionable